Protalix BioTherapeutics (PLX) Shares Outstanding (Diluted Average) (2012 - 2025)

Protalix BioTherapeutics has reported Shares Outstanding (Diluted Average) for 12 years, with the latest figure at $76.6 million in Q1 2025.

• For the quarter ending Q1 2025, Shares Outstanding (Diluted Average) rose 4.9% year-over-year to $76.6 million; the trailing twelve-month figure through Mar 2025 stood at $76.6 million (up 4.9% YoY), and the FY2022 full-year result was $48.5 million, up 9.81% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2025 stood at $76.6 million, up from $73.2 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $83.2 million in Q2 2023, with the low at $39.9 million in Q1 2021.
• Average Shares Outstanding (Diluted Average) over 5 years is $55.8 million, with a median of $47.6 million recorded in 2022.
• Year-over-year, Shares Outstanding (Diluted Average) jumped 75.8% in 2023 and declined 12.05% in 2024.
• Tracing PLX's Shares Outstanding (Diluted Average) over 5 years: stood at $44.1 million in 2021, then increased by 9.81% to $48.5 million in 2022, then jumped by 71.65% to $83.2 million in 2023, then declined by 12.05% to $73.2 million in 2024, then advanced by 4.7% to $76.6 million in 2025.
• The last three Shares Outstanding (Diluted Average) figures came in at $76.6 million (Q1 2025), $73.2 million (Q2 2024), and $73.0 million (Q1 2024), per Business Quant data.

Peer Comparison